Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report)’s stock price was down 3.2% during mid-day trading on Thursday . The stock traded as low as $12.96 and last traded at $12.98. Approximately 93,077 shares traded hands during trading, a decline of 85% from the average daily volume of 607,855 shares. The stock had previously closed at $13.41.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating for the company.
Read Our Latest Report on TNXP
Tonix Pharmaceuticals Price Performance
Institutional Trading of Tonix Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Investments LP purchased a new stake in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $66,000. Point72 Asset Management L.P. purchased a new stake in Tonix Pharmaceuticals during the 4th quarter valued at approximately $526,000. Jane Street Group LLC raised its stake in Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals during the 4th quarter valued at approximately $162,000. Finally, Geode Capital Management LLC raised its stake in Tonix Pharmaceuticals by 1,600.1% during the 4th quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock valued at $650,000 after acquiring an additional 1,855,907 shares during the last quarter. 82.26% of the stock is owned by hedge funds and other institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
- Five stocks we like better than Tonix Pharmaceuticals
- Business Services Stocks Investing
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Choose Top Rated Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- Do ETFs Pay Dividends? What You Need to Know
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.